Beiersdorf and S-Biomedic announced that has signed a cooperation agreement for the joint development of the technology of skin care, by studying the microbiome of the skin. One of the provisions of this agreement indicates that the company Beiersdorf invests in the S-Biomedic 1 million euros.
“Since 1882 Beiersdorf has successfully developed partnerships with suppliers, universities, research institutes, and individual inventors and innovators. With our investment in S-Biomedic, we open new prospects for cooperation with startups. These pioneers in the field of future technologies will help us to find something that would eliminate the unfulfilled needs of consumers,” said Ralph Gusko, member of the Council on consumer brands at Beiersdorf.
While the key role microbiome has been well researched in the functioning of the intestines, microorganisms of the skin were mainly associated only with a disease or an unpleasant odor. With the advent of sequencing technologies the next generation of knowledge about the delicate balance of the skin microbiome and its symbiotic effects on the metabolism of the skin grow exponentially. In particular, based on a similar study has developed new approaches in the treatment of acne.
“Skin care will benefit greatly from the modern development of biological science. Study microbion is one of the most dynamic areas, and we need to study deeply for his innovative offers for consumers,” said Dr. May, Sanaa, senior Vice President, research and development for Beiersdorf.
“We are happy to use Beiersdorf extensive experience in the field of skin care, so our research has reached the following stage of commercialization with maximum speed and efficiency,” said Veronica Odowa, CEO of S-Biomedic.
Beiersdorf is one of the many cosmetic companies that studies the influence of microorganisms present on the skin, on her condition. For example, in February of this year it was announced that Givaudan reinforces research findings on the skin microbiome.